Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Bayer508 enrolled

Overview

This study examines the long term safety and efficacy of the Fixed Dose combination BAY98-7106 (nifedipine plus candesartan primarily at the highest dose in development) in patients with moderate to severe hypertension. Patients meeting the entry criteria, will receive the Fixed Dose combination for 28 weeks, including 8 weeks with stepwise dose increase up to the high target dose. The first 200 subjects completing 28 weeks will continue treatment for additional 24 weeks (52 weeks in total). Subjects who do not tolerate an increased dose will be treated at their highest tolerable dose.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

508

Conditions

Hypertension

Interventions

Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must have moderate to severe essential hypertension (Grade 2 or Grade 3, WHO classifications). At Visit 1, subjects not treated with antihypertensive medications are to have MSSBP of \>/= 160 mmHg and \< 200 mmHg, as measured by a calibrated electronic BP measuring device. For other subjects who are treated with antihypertensive medication before, they should have MSSBP \>/= 160 mmHg and \<200 mmHg after wash out. * Women of childbearing potential and men must agree to use adequate contraception other than hormonal contraceptives when sexually active Exclusion Criteria: * Mean seated systolic blood pressure \>/= 200 mmHg and/or mean seated diastolic blood pressure \>/= 120 mm/Hg * Mean seated diastolic blood pressure \< 60 mm/Hg * Differences greater than 20 mmHg for systolic blood pressure and 10 mmHg for diastolic blood pressure are present on 3 consecutive blood pressure readings at visit 0 * Any history of hypertensive emergency * Evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma, hyperaldosteronism, etc. * Cerebrovascular ischemic event (stroke, transient ischemic attack \[TIA\])within the previous 12 months * History of intracerebral hemorrhage or subarachnoid hemorrhage * History of hypertensive retinopathy - known Keith-Wagener Grade III or IV * Any history of heart failure, New York Heart Association (NYHA) classification III or IV * Severe coronary heart disease as manifest by a history of myocardial infarction or unstable angina in the last 6 months prior to visit 0 * Type 1 diabetes mellitus (DM) or poorly controlled Type 2 DM as evidenced by HbA1C of greater than 9% on visit 0. * Hyperkalemia: potassium above the upper limit of normal in the laboratory range

Locations (82)

Unnamed facility

Foley, Alabama, United States

Unnamed facility

Carmichael, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Spring Valley, California, United States

Unnamed facility

Milford, Connecticut, United States

Unnamed facility

Outcomes

Primary Outcomes

Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28

An adverse event (AE) is any untoward medical occurrence (that is, any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study. AEs were considered to be treatment-emergent if they had started or worsened after first application of study medication.

Time frame: From the time of first study drug administration up to Week 28

Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28

An AE is any untoward medical occurrence (that is, any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study. AEs were considered to be treatment-emergent if they had started or worsened after first application of study medication. TEAEs of special interest included the incidence of symptomatic hypotension and the incidence and severity of vasodilatory adverse events (such as oedema, headache, and flushing). Only subjects who had TEAEs of special interest as mild, moderate or severe were reported.

Time frame: From the time of first study drug administration up to Week 28

Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)

Time frame: From the time of first study drug administration up to Week 52/EOS

Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)

Time frame: From the time of study treatment up to Week 52/EOS

Secondary Outcomes

Number of Subjects With Clinically Relevant Changes in Laboratory Parameters

Laboratory evaluations of blood and urine samples were performed, including hematology (hematocrit, hemoglobin, red blood cells count, white blood cells count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets), blood chemistry (sodium, potassium, chloride, bicarbonate, uric acid, total protein, albumin, calcium, blood urea nitrogen, creatinine, aspartate transaminase, alanine transaminase, lactate dehydrogenase, gamma glutamyl transferase, alkaline phosphatase, creatine kinase, total bilirubin, direct bilirubin, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, fasting glucose), urinalysis (pH, blood, specific gravity, glucose, protein, cells/sediment). A laboratory test abnormality considered clinically relevant, for example, causing withdrawal by subject, requiring treatment or causing apparent clinical manifestations, or judged relevant by the investigator, were reported as AEs.

Time frame: Baseline (Week 0) up to Week 52/EOS

Change From Baseline In Mean Seated Systolic Blood Pressure (MSSBP) At Weeks 28 And 52

Time frame: Baseline (Week 0), Weeks 28 and 52

Change From Baseline in Mean Seated Diastolic Blood Pressure (MSDBP) at Weeks 28 and 52

Time frame: Baseline (Week 0), Weeks 28 and 52

Blood Pressure Control Rate at Weeks 28 and 52

Control rate was defined as the percentage of subjects that reached a predetermined blood pressure (BP) target of BP less than (\<) 140/90 mmHg.

Time frame: Weeks 28 and 52

Blood Pressure Response Rate at Weeks 28 and 52

Response rate was defined as the percentage of subjects who achieved a systolic blood pressure response (MSSBP of \<140 mmHg or a reduction of MSSBP of more than (\>) 20 mmHg from baseline value), or a diastolic blood pressure response (MSDBP of \<90 mmHg or a reduction of MSDBP of \>10 mmHg from baseline value).

Time frame: Weeks 28 and 52